↓ Skip to main content

Benzodiazepines for restless legs syndrome

Overview of attention for article published in Cochrane database of systematic reviews, March 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
15 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Benzodiazepines for restless legs syndrome
Published in
Cochrane database of systematic reviews, March 2017
DOI 10.1002/14651858.cd006939.pub2
Pubmed ID
Authors

Karla Carlos, Gilmar F Prado, Camila DM Teixeira, Cristiane Conti, Marcio M de Oliveira, Lucila BF Prado, Luciane BC Carvalho

Abstract

Restless legs syndrome (RLS) is a common disease affecting about 5% to 15% of the population. Symptoms of RLS can be severe in a minority of and can have a major impact on sleep, mostly sleep initiation, and quality of life. Benzodiazepines are drugs that can induce and maintain sleep and, hence, intuitively are thought to be beneficial to people with RLS. Altough benzodiazepines, particularly clonazepam, are used to treat RLS symptoms, a systematic review done by the American Academy of Sleep Medicine stated that benzodiazepines should not be used as a first-line treatment, although could be used as a coadjuvant therapy. To evaluate the efficacy and safety of benzodiazepine compared to placebo or other treatment for idiopathic RLS, including unconfounded trials comparing benzodiazepines versus open control. In March 2016 we searched CENTRAL, MEDLINE, Embase and LILACS We checked the references of each study and contacted study authors to identify any additional studies. We considered studies published in any language. Randomised clinical trials of benzodiazepine treatment in idiopathic RLS. We did not perform data collection and analysis, since we did not include any studies, MAIN RESULTS: We did not identify any studies that met the inclusion criteria of the review. Two cross-over studies are awaiting classification because the cross-over trials did not give data at the end of the first cross-over period. The effectiveness of benzodiazepines for RLS treatment is currently unknown.

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 21%
Student > Master 12 20%
Researcher 11 18%
Other 4 7%
Professor > Associate Professor 3 5%
Other 11 18%
Unknown 7 11%
Readers by discipline Count As %
Medicine and Dentistry 27 44%
Nursing and Health Professions 5 8%
Psychology 4 7%
Social Sciences 3 5%
Neuroscience 3 5%
Other 8 13%
Unknown 11 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2019.
All research outputs
#1,370,761
of 14,218,657 outputs
Outputs from Cochrane database of systematic reviews
#3,892
of 10,894 outputs
Outputs of similar age
#40,752
of 264,306 outputs
Outputs of similar age from Cochrane database of systematic reviews
#111
of 260 outputs
Altmetric has tracked 14,218,657 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,894 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.7. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,306 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 260 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.